Search Results for "treatment guidelines"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for treatment guidelines. Results 411 to 420 of 432 total matches.
Two New Drugs for Skin and Skin Structure Infections
The Medical Letter on Drugs and Therapeutics • Aug 18, 2014 (Issue 1449)
and Skin
Structure Infections
The FDA has approved two new drugs for treatment
of adults with acute ...
The FDA has approved two new drugs for treatment
of adults with acute bacterial skin and skin structure
infections caused by susceptible gram-positive
bacteria. Dalbavancin (Dalvance – Durata) is a long-acting
intravenous (IV) lipoglycopeptide antibiotic
similar to telavancin (Vibativ). Tedizolid phosphate
(Sivextro – Cubist) is an IV and oral oxazolidinone
antibacterial drug similar to linezolid (Zyvox). A
third IV antibiotic, oritavancin (Orbactiv), recently
approved by the FDA for the same indication, will be
reviewed in a future...
IV Artesunate for Severe Malaria
The Medical Letter on Drugs and Therapeutics • Aug 10, 2020 (Issue 1604)
. Treatment of malaria: guidelines for clinicians (United
States). Available at: www.cdc.gov/malaria ...
Artesunate for injection (Amivas LLC), a semi-synthetic
artemisinin derivative, is now approved
by the FDA for initial (induction) treatment of severe
malaria in children and adults. It has been available
from the CDC on a compassionate use basis since
2007. Artemether/lumefantrine (Coartem), another
artemisinin-based drug, was approved earlier for oral
treatment of uncomplicated Plasmodium falciparum
malaria. IV artesunate is now the only FDA-approved
injectable antimalarial drug available in the US; IV
quinidine has been discontinued.
Primary Prevention of Ulcers in Patients Taking Aspirin or NSAIDs
The Medical Letter on Drugs and Therapeutics • Mar 08, 2010 (Issue 1333)
tabs.
1. Cost for 30 days' treatment at the lowest dosage, according to AWP listings of prescription ...
Aspirin and other nonsteroidal anti-inflammatory drugs (NSAIDs) are common causes of peptic ulcer disease. Patients infected with Helicobacter pylori who take aspirin or another NSAID have an especially high risk. Drugs that have been tried for prevention of ulcers in patients taking NSAIDs including H2-receptor antagonists, proton pump inhibitors (PPIs), aluminum- or magnesium-containing antacids, the prostaglandin misoprostol (Cytotec, and others), and antibiotics to eradicate H. pylori.Click here to view the free full...
Elbasvir/Grazoprevir (Zepatier) for Hepatitis C
The Medical Letter on Drugs and Therapeutics • Feb 29, 2016 (Issue 1489)
— elbasvir, an NS5A inhibitor, and grazoprevir,
an NS3/4A protease inhibitor — for oral treatment ...
The FDA has approved Zepatier (Merck), a fixed-dose
combination of two direct-acting antiviral
agents — elbasvir, an NS5A inhibitor, and grazoprevir,
an NS3/4A protease inhibitor — for oral treatment
of chronic hepatitis C virus (HCV) genotype 1 or 4
infection.
Lefamulin (Xenleta) for Community-Acquired Bacterial Pneumonia
The Medical Letter on Drugs and Therapeutics • Sep 23, 2019 (Issue 1581)
), a semisynthetic
pleuromutilin antibiotic, has been approved by the
FDA for IV and oral treatment of community ...
Lefamulin (Xenleta – Nabriva), a semisynthetic
pleuromutilin antibiotic, has been approved by the
FDA for IV and oral treatment of community-acquired
bacterial pneumonia (CABP) in adults. It is the first
systemic pleuromutilin antibiotic to be approved in the
US; retapamulin (Altabax), a 1% topical ointment for
treatment of impetigo, was approved in 2007.
Lebrikizumab (Ebglyss) for Atopic Dermatitis
The Medical Letter on Drugs and Therapeutics • Nov 11, 2024 (Issue 1715)
, for treatment of moderate to severe
atopic dermatitis that has not been or cannot be
adequately treated ...
The FDA has approved lebrikizumab-lbkz (Ebglyss –
Lilly), a subcutaneously injected interleukin (IL)-13
antagonist, for treatment of moderate to severe
atopic dermatitis that has not been or cannot be
adequately treated with topical therapy in patients ≥12
years old (weight ≥40 kg). Lebrikizumab is the third
subcutaneously injected human IgG4 monoclonal
antibody to be approved in the US for this indication.
Tralokinumab (Adbry), another IL-13 antagonist, is
also approved for use in patients ≥12 years old, and
dupilumab (Dupixent), an IL-4 and IL-13 inhibitor, is
approved for...
Med Lett Drugs Ther. 2024 Nov 11;66(1715):179-81 doi:10.58347/tml.2024.1715b | Show Introduction Hide Introduction
Drugs for GERD and Peptic Ulcer Disease
The Medical Letter on Drugs and Therapeutics • Apr 04, 2022 (Issue 1647)
infection. Annu Rev Med 2022; 73:183.
26. WD Chey et al. ACG clinical guideline: treatment of
Helicobacter ...
Gastroesophageal reflux disease (GERD) is the most
common GI condition encountered in the outpatient
setting; it affects about 20% of people in the US.
Drugs for Chronic Heart Failure
The Medical Letter on Drugs and Therapeutics • May 26, 2025 (Issue 1729)
or mid-range ejection fraction.1,2
HF WITH REDUCED EJECTION FRACTION
STANDARD TREATMENT — All patients ...
Pharmacologic management of chronic heart failure
(HF) is primarily determined by the patient's left
ventricular ejection fraction (LVEF) and severity of
symptoms. Patients with chronic HF who have an
LVEF ≤40% are considered to have heart failure with
reduced ejection fraction (HFrEF) and those with an
LVEF ≥50% are considered to have heart failure with
preserved ejection fraction (HFpEF). Patients with an
LVEF of 41-49% have heart failure with mildly reduced
or mid-range ejection fraction.
Med Lett Drugs Ther. 2025 May 26;67(1729):81-8 doi:10.58347/tml.2025.1729a | Show Introduction Hide Introduction
Drugs for COPD
The Medical Letter on Drugs and Therapeutics • Sep 02, 2024 (Issue 1710)
for Chronic Obstructive Lung
Disease) guidelines for treatment of COPD were
updated recently.1 Treatment ...
The main goals of treatment of chronic obstructive
pulmonary disease (COPD) are to relieve symptoms,
reduce the frequency and severity of exacerbations,
prevent disease progression, and reduce mortality.
GOLD (Global Initiative for Chronic Obstructive Lung
Disease) guidelines for treatment of COPD were
updated recently. Treatment of acute exacerbations
is not discussed here. Drugs available for treatment
of COPD are listed in Tables 1 and 3.
Med Lett Drugs Ther. 2024 Sep 2;66(1710):137-44 doi:10.58347/tml.2024.1710a | Show Introduction Hide Introduction
Opioids for Pain
The Medical Letter on Drugs and Therapeutics • Dec 12, 2022 (Issue 1665)
Opioids for Pain
A new CDC guideline for prescribing opioids for pain
recently became available.1 ...
A new CDC guideline for prescribing opioids for pain
recently became available. Nonopioid drugs for pain
were reviewed in a previous issue.